Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$2.39
-2.4%		$2.55
$0.76
▼
$3.54
$155.35M1.82517,804 shs232,753 shs
Generation Bio Co. stock logo
GBIO
Generation Bio
$5.34
$5.48
$3.00
▼
$6.95
$35.99M2.05160,744 shsN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.11
-0.9%		$2.26
$0.41
▼
$3.43
$134.46M-0.01267,196 shs99,652 shs
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.13
-3.7%		$4.82
$2.33
▼
$8.51
$140.39M1.79212,662 shs81,035 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
-2.45%+3.46%+4.82%-17.59%+25.13%
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%0.00%0.00%0.00%-15.91%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-0.94%+5.50%+3.43%-6.64%-27.24%
Oncocyte Corp stock logo
IMDX
Oncocyte
-3.73%-4.84%-5.49%-33.49%+412,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$2.39
-2.4%		$2.55
$0.76
▼
$3.54
$155.35M1.82517,804 shs232,753 shs
Generation Bio Co. stock logo
GBIO
Generation Bio
$5.34
$5.48
$3.00
▼
$6.95
$35.99M2.05160,744 shsN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.11
-0.9%		$2.26
$0.41
▼
$3.43
$134.46M-0.01267,196 shs99,652 shs
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.13
-3.7%		$4.82
$2.33
▼
$8.51
$140.39M1.79212,662 shs81,035 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
-2.45%+3.46%+4.82%-17.59%+25.13%
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%0.00%0.00%0.00%-15.91%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-0.94%+5.50%+3.43%-6.64%-27.24%
Oncocyte Corp stock logo
IMDX
Oncocyte
-3.73%-4.84%-5.49%-33.49%+412,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Equillium, Inc. stock logo
EQ
Equillium
2.91
Moderate Buy$7.57216.80% Upside
Generation Bio Co. stock logo
GBIO
Generation Bio
2.17
Hold$8.5059.18% Upside
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
2.67
Moderate Buy$9.00326.54% Upside
Oncocyte Corp stock logo
IMDX
Oncocyte
2.33
Hold$10.50154.24% Upside

Current Analyst Ratings Breakdown

Latest GBIO, IMDX, EQ, and HURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$9.00
8/18/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/11/2026
Equillium, Inc. stock logo
EQ
Equillium
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/21/2026
Equillium, Inc. stock logo
EQ
Equillium
Clear Str Llc logo
Clear Str
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/17/2026
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
7/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/24/2026
Equillium, Inc. stock logo
EQ
Equillium
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Equillium, Inc. stock logo
EQ
Equillium
$41.10M3.69N/AN/A$0.88 per share2.72
Generation Bio Co. stock logo
GBIO
Generation Bio
$19.89M1.81N/AN/A$12.91 per share0.41
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.29 per shareN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.05M33.37N/AN/A($0.65) per share-6.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Equillium, Inc. stock logo
EQ
Equillium
-$22.40M-$0.20N/AN/AN/AN/A-41.15%-38.29%11/12/2026 (Estimated)
Generation Bio Co. stock logo
GBIO
Generation Bio
-$131.67M-$9.34N/AN/AN/A-410.13%-94.82%-34.13%N/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$30.05M-$0.54N/AN/AN/AN/A-156.47%-106.98%11/13/2026 (Estimated)
Oncocyte Corp stock logo
IMDX
Oncocyte
-$50.22M-$1.49N/AN/AN/A-2,955.63%N/A-107.52%N/A

Latest GBIO, IMDX, EQ, and HURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.1533-$0.14+$0.0133-$0.14N/AN/A
8/13/2026Q2 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.0540-$0.04+$0.0140-$0.04N/AN/A
8/10/2026Q2 2026
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A-$0.23N/A-$0.31N/A$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
N/AN/AN/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Equillium, Inc. stock logo
EQ
Equillium
N/A
23.40
23.40
Generation Bio Co. stock logo
GBIO
Generation Bio
N/A
4.44
4.44
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20
0.18
0.18
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A
2.00
1.98

Institutional Ownership

CompanyInstitutional Ownership
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Generation Bio Co. stock logo
GBIO
Generation Bio
95.22%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%
Oncocyte Corp stock logo
IMDX
Oncocyte
55.35%

Insider Ownership

CompanyInsider Ownership
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Generation Bio Co. stock logo
GBIO
Generation Bio
21.10%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
6.06%
Oncocyte Corp stock logo
IMDX
Oncocyte
2.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Equillium, Inc. stock logo
EQ
Equillium
4063.41 million52.10 millionNot Optionable
Generation Bio Co. stock logo
GBIO
Generation Bio
1506.74 million5.32 millionOptionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A63.73 million59.87 millionN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
12032.72 million32.00 millionN/A

Recent News About These Companies

Oncocyte (NASDAQ:IMDX) Earns "Buy" Rating from Needham & Company LLC
August 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971279
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
August 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4937395-insight-molecular-diagnostics-inc-imdx-discusses-advances-in-heart-transplant-rejection
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncocyte-eyes-faster-less-invasive-heart-transplant-rejection-testing-2026-08-17/
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343161/0/en/insight-molecular-diagnostics-to-host-virtual-kol-event-on-august-17-2026-moving-toward-in-house-heart-transplanted-organ-rejection-testing.html
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934501-insight-molecular-diagnostics-inc-imdx-q2-2026-earnings-call-transcript
Oncocyte Q2 Earnings Call Highlights
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncocyte-q2-earnings-call-highlights-2026-08-10/
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338155/0/en/imdx-to-release-second-quarter-results-on-august-10-2026-and-attend-needham-virtual-medtech-diagnostics-1x1-conference.html
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332069/0/en/imdx-graftassure-assay-guides-use-of-potentially-kidney-graft-saving-drug-in-new-lancet-group-publication.html
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328769/0/en/favorable-medicare-coverage-decision-supports-commercial-adoption-of-imdx-graftassure-assay-portfolio.html
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318899/0/en/imdx-chief-science-officer-ekkehard-schuetz-publishes-200th-research-paper.html
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315564/0/en/imdx-and-the-american-society-of-transplant-surgeons-announce-recipients-of-the-asts-imdx-health-economics-research-grant.html
Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
June 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3313008/0/en/favorable-head-to-head-data-on-imdx-s-graftassure-with-competing-ngs-assay-published-in-clinical-chemistry.html
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310800/0/en/imdx-graftassure-assay-sets-new-standard-in-screening-kidney-transplant-patients-per-american-journal-of-transplantation.html
Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript
June 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4914322-insight-molecular-diagnostics-inc-imdx-shareholder-analyst-call-prepared-remarks-transcript
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3309318/0/en/imdx-to-highlight-in-house-transplant-testing-opportunity-and-host-key-opinion-leaders-at-american-transplant-congress.html
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4904299-insight-molecular-diagnostics-inc-imdx-q1-2026-earnings-call-transcript
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294423/0/en/imdx-reports-q1-2026-results-and-update-on-progress-toward-graftassure-commercialization.html
iMDx to Release First Quarter 2026 Results on May 13, 2026
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3289337/0/en/imdx-to-release-first-quarter-2026-results-on-may-13-2026.html
Insider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires 38,880 Shares of Stock
April 28, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-imdx-insider-buying-and-selling-2026-04-28/
Broadwood Partners, L.P. Purchases 40,114 Shares of Oncocyte (NASDAQ:IMDX) Stock
April 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-imdx-insider-buying-and-selling-2026-04-21/
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273304/0/en/real-world-evidence-and-industry-momentum-builds-for-imdx-s-flagship-graftassure-assay.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Electrical substation with transmission towers and power lines in the foreground, with a city skyline at sunset in the background.
3 Dividend Champion Utilities for a Market That Can't Sit Still
By Dan Schmidt | August 10, 2026
Digital display of multiple financial charts, including line, candlestick, bar, heat map, and scatter plot graphs.
3 Unexpected ETFs Crushing the Market This Summer
By Nathan Reiff | August 16, 2026
Rendering of an electric vertical takeoff aircraft (eVTOL) on a rooftop landing pad above a city skyline.
Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
By Jeffrey Neal Johnson | August 13, 2026
Joby Aviation electric vertical takeoff aircraft flying at sunset with the Joby logo displayed.
Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
By Jeffrey Neal Johnson | August 13, 2026
Equillium stock logo

Equillium NASDAQ:EQ

$2.39 -0.06 (-2.45%)
As of 08/28/2026 04:00 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Generation Bio stock logo

Generation Bio NASDAQ:GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.11 -0.02 (-0.94%)
As of 08/28/2026 04:00 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Oncocyte stock logo

Oncocyte NASDAQ:IMDX

$4.13 -0.16 (-3.73%)
As of 08/28/2026 04:00 PM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas